Antifibrotic drugs in connective tissue disease-related interstitial lung disease (CTD-ILD): from mechanistic insights to therapeutic applications

Antifibrotic drugs in connective tissue disease-related interstitial lung disease (CTD-ILD): from mechanistic insights to therapeutic applications

Fibrosing interstitial lung disease (ILD) is one of the most important causes of morbidity and mortality in patients with connective tissue diseases (CTDs), which include systemic sclerosis, rheumatoid arthritis, Sjögren’s syndrome, idiopathic inflammatory myositis and systemic lupus erythematosus....

Full description

Bibliographic Details
Main Authors: Gian Luca Erre, Marco Sebastiani, Andreina Manfredi, Elisabetta Gerratana, Fabiola Atzeni, Giuseppe Passiu, Arduino A Mangoni
Format: Article
Language:English
Published: BioExcel Publishing Ltd 2021-01-01
Series:Drugs in Context
Subjects:
connective tissue diseases
idiopathic inflammatory myopathies
interstitial lung disease
pirfenidone
nintedanib
rheumatoid arthritis
sjögren’s syndrome
systemic sclerosis
Online Access:https://www.drugsincontext.com/antifibrotic-drugs-in-connective-tissue-disease-related-interstitial-lung-disease-(ctd-ild):-from-mechanistic-insights-to-therapeutic-applications

Internet

https://www.drugsincontext.com/antifibrotic-drugs-in-connective-tissue-disease-related-interstitial-lung-disease-(ctd-ild):-from-mechanistic-insights-to-therapeutic-applications

Similar Items